survodutide mastery course
Unit 6 of 12
Weight Loss and Metabolic Effects
Phase 2 dose-response data and metabolic improvements beyond body weight
Beyond a GLP-1 Agonist
Survodutide produced up to 18.7% body weight loss at 46 weeks in Phase 2, with simultaneous improvements in glycemic control, liver fat, and cardiometabolic markers. This unit breaks down the dose-response curve, the diabetes trial data, and the metabolic effects that extend beyond the scale.
This unit is provided for educational purposes only and is not medical advice. Consult your physician before making any health decisions.
Interactive Clinical Results
Explore dose-dependent outcomes across the Phase 2 obesity and diabetes trials.
clinical results dashboard
key numbers
headline results from the Phase 2 obesity trial at 46 weeks.
-14.9%
ITT weight loss at 4.8 mg (46 weeks)
-18.7%
on-treatment weight loss at 4.8 mg
387
patients enrolled across 5 dose arms
62%
completion rate at highest dose
Weight loss data are from a Phase 2 trial (n=387) with a 46-week treatment period. Phase 3 trials (SYNCHRONIZE-1/2) use a 76-week treatment period with a higher maximum dose (6.0 mg vs 4.8 mg) and a slower escalation schedule. Final Phase 3 results may differ substantially from the Phase 2 numbers reported here.
key terms
clinical trial and metabolic vocabulary for this unit. tap to expand.
I
Intention-to-treat. Includes all randomized patients regardless of whether they completed the trial. Dropouts dilute the observed effect, making ITT results more conservative than on-treatment analyses.
O
Includes only patients who completed the full treatment period. Shows the actual effect in people who tolerated the drug. The gap between ITT and on-treatment values reflects the dropout rate.
D
The relationship between drug dose and observed effect. Survodutide showed a clear dose-response from 0.6 mg (-6.2%) through 4.8 mg (-14.9%), with diminishing returns between 3.6 mg and 4.8 mg suggesting near-maximal GLP-1R engagement.
R
Resting energy expenditure. The calories burned at rest. GCGR activation increases REE through hepatic beta-oxidation and thermogenesis, distinguishing survodutide from pure GLP-1 agonists that primarily reduce caloric intake.
F
Fibroblast growth factor 21. A hormone secreted by the liver in response to GCGR activation. Drives fatty acid oxidation, improves insulin sensitivity, and reduces hepatic lipid accumulation. Survodutide's GCGR arm upregulates FGF21 as part of its metabolic benefit beyond weight loss.
dose-response at 46 weeks
weight loss across all five arms of the Phase 2 obesity trial. ITT analysis.
placebo
-2.8% body weight (n=61). lifestyle counseling only. 71% completion rate.
0.6 mg
-6.2% body weight (n=60). subtherapeutic GCGR engagement. 80% completion.
2.4 mg
-12.5% body weight (n=61). clinically meaningful. 75% completion.
3.6 mg
-13.2% body weight (n=61). diminishing returns vs 2.4 mg. 69% completion.
4.8 mg
-14.9% body weight (n=60). -18.7% on-treatment. highest GI burden. 62% completion.